about
In vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio choleraeReduced antibody response to streptavidin through site-directed mutagenesisGPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopeniaNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Development of neuropeptide drugs that cross the blood-brain barrier.Polyethylene glycol (PEG) linked to near infrared (NIR) dyes conjugated to chimeric anti-carcinoembryonic antigen (CEA) antibody enhances imaging of liver metastases in a nude-mouse model of human colon cancer.Polymeric nanomedicine for cancer MR imaging and drug deliveryEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan diseaseEnhanced brain distribution of modified aspartoacylase.Engineering biomaterial systems to enhance viral vector gene delivery.Solubilization of native integral membrane proteins in aqueous buffer by noncovalent chelation with monomethoxy poly(ethylene glycol) (mPEG) polymers.Coarse-grained model for PEGylated lipids: effect of PEGylation on the size and shape of self-assembled structuresPolymeric oncolytic adenovirus for cancer gene therapy.Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy.Physico-chemical modifications of conjugated linoleic acid for ruminal protection and oxidative stability.Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers.Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a.PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria.Design of Stable α-Helical Peptides and Thermostable Proteins in Biotechnology and Biomedicine.Delivery of therapeutic proteins.PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.Design of a heterotetravalent synthetic allergen that reflects epitope heterogeneity and IgE antibody variability to study mast cell degranulationPolyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.Fully degradable hydrophilic polyals for protein modification.Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates.Delivery of neuropeptides from the periphery to the brain: studies with enkephalin.Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.Unexpected enhancement in biological activity of a GPCR ligand induced by an oligoethylene glycol substituentA phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia.Nanostructured Polymer Thin Films Fabricated with Brush-based Layer-by-Layer Self-assembly for Site-selective Construction and Drug release.Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF.
P2860
Q24647817-5A4F2F8C-F167-46F7-9FB5-55F4C1C881A6Q28364576-5C974D58-7AC3-4FF2-A462-8E343C1AAD68Q33499685-05DE7B62-C907-427A-A2BE-AA86674DC3F7Q33559298-045A78E1-97CC-4AAB-839A-874A2A89F8DBQ33569277-92FA7998-129C-4107-88C7-C82083D0EAA5Q33654731-83E99C52-DB8D-4CB5-A1A8-E06FCB9403CBQ33773418-20838BE7-96B7-4BD5-95CC-E4861063A13DQ34069571-AA4FE60A-045D-44B0-8952-203302B7615CQ34500635-3BD6F72C-4415-4AAD-AED1-C33D80A1CBB1Q34616189-8B202484-6387-4F38-838B-D90A88BE08E3Q35144415-506D07FA-7F39-4391-A120-C8C26F19B012Q35178588-F0E21E92-662D-47BE-B39C-419E5D6F74A9Q36290628-ED28F018-B75F-48F5-B21B-863F3FE9DFD8Q36344901-297DA3BF-E6B1-459A-81F1-DEC6B6125218Q36671748-1E7FB149-D71D-4BB0-B7E1-909829CFAA20Q36726308-D1ABC8ED-F1A8-4055-BCEB-CED74ACDC10EQ36897485-0AD29A7A-5317-4BD9-90BF-626DE074DD77Q36920409-A2AADF36-FD11-4BC9-9111-66BDB6CBB36AQ36940229-1F238DFB-14A5-4292-9665-171BBFA720C0Q37480507-BDDD49EC-82D2-443A-9AFC-9EFBC3D29F7AQ37544873-0E0F156C-AB4A-4D41-9D50-B56CE0718C90Q37668486-F156CE76-654A-45FC-A528-367F2CF830AEQ38281206-E06B1E89-29B6-4F97-9185-FFD40BCFA9E1Q39351354-55C34C05-6DC5-4E53-8FC3-7F48EDF243E9Q39991117-F0F27F31-2619-41B2-9F7A-BA80DD9290BCQ40223801-4795800D-2283-4D32-A35E-A151BA014A73Q40402078-8FA16963-0D92-4516-84A3-26CA3C8394BAQ41931863-97377569-D05D-411A-8F2B-A9B05BC692A8Q42607562-8E76C93A-0D48-4D56-A90B-91D5A7FF18BEQ42627049-C8874096-1C29-4AF5-8AFE-351BF9950B19Q47106934-FF212870-071C-4CAD-A9EA-0CA13543C6C7Q49789651-B243D35D-29B9-4681-92A0-1F2DE530F41EQ55248103-CE666E1D-0CFD-492E-919C-F9AEFC23220E
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The uses and properties of PEG-linked proteins.
@ast
The uses and properties of PEG-linked proteins.
@en
type
label
The uses and properties of PEG-linked proteins.
@ast
The uses and properties of PEG-linked proteins.
@en
prefLabel
The uses and properties of PEG-linked proteins.
@ast
The uses and properties of PEG-linked proteins.
@en
P2093
P1476
The uses and properties of PEG-linked proteins.
@en
P2093
P304
P577
1992-01-01T00:00:00Z